Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial
Jeremy Pettus, Schafer Boeder, Mark P. Christiansen, Douglas Denham, Timothy S. Bailey, Halis Kaan Aktürk, Leslie J. Klaff, Julio Rosenstock, Mickie H. M. Cheng, Bruce W. Bode, Edgar Bautista, Ren Xu, Hai Yan, Dung Thai, Satish K. Garg, Samuel Klein
Topics & Concepts
MedicinePlaceboInternal medicineGlycemicInsulinGlucagonDiabetes mellitusType 1 diabetesClinical endpointType 2 diabetesGlucagon receptorRandomized controlled trialGastroenterologyEndocrinologyAlternative medicinePathologyPancreatic function and diabetesDiabetes Treatment and ManagementDiabetes Management and Research